The ROE as of September 2024 (TTM) for Imunon, Inc. (IMNN) is -165.51%

According to Imunon, Inc.’s latest financial reports and current stock price. The company's current ROE is -165.51%. This represents a change of 173.88% compared to the average of -60.43% of the last 4 quarters.

Imunon, Inc. (IMNN) Historical ROE (quarterly & annually)

How has IMNN ROE performed in the past?

The mean historical ROE of Imunon, Inc. over the last ten years is -118.57%. The current -165.51% ROE has changed 39.59% with respect to the historical average. Over the past ten years (40 quarters), IMNN's ROE was at its highest in in the December 2018 quarter at 26.27%. The ROE was at its lowest in in the March 2023 quarter at -272.04%.

Imunon, Inc. (IMNN) ROE by Quarter and Year

Discovering the peaks and valleys of Imunon, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Imunon, Inc. (IMNN) Average ROE

How has IMNN ROE performed in the past?

The current ROE of Imunon, Inc. (IMNN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Imunon, Inc. (IMNN) ROE vs. Peers

How is IMNN’s ROE compared to its peers?

Imunon, Inc.’s ROE is greater than Exicure, Inc. (-288.03%), greater than Cyclacel Pharmaceuticals, Inc. (-1873.74%), greater than Histogen Inc. (-108.33%), greater than DiaMedica Therapeutics Inc. (-38.56%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Senti Biosciences, Inc. (-91.09%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Quoin Pharmaceuticals, Ltd. (-112.11%), greater than SAB Biotherapeutics, Inc. (-94.04%), less than Cingulate Inc. (11.47%), less than Bellicum Pharmaceuticals, Inc. (153.34%), greater than Lisata Therapeutics, Inc. (-46.22%), greater than Lixte Biotechnology Holdings, Inc. (-112.90%), less than Kineta, Inc. (934.78%), greater than Theriva Biologics, Inc. (-61.28%), greater than Lumos Pharma, Inc. (-157.99%), greater than Diffusion Pharmaceuticals Inc. (-55460.19%), less than Avalo Therapeutics, Inc. (178.36%), less than Catalyst Biosciences, Inc. (1.20%),

Build a custom stock screener for Imunon, Inc. (IMNN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Imunon, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Imunon, Inc. (IMNN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Imunon, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.